Value of combined XCT/SPECT technology for avoiding false positive planar 123I-MIBG scintigraphy

Özer, Senem Yiğit; Dobrozemsky, Georg; Kienast, Oskar; Beheshti, Mohsen; Becherer, Alexander; Niederle, Bruno; Kainberger, Franz; Dudczak, Robert; Kurtaran, Amir

doi:10.1055/s-0038-1625200

Cited by 33 publications

(19 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(12) tarafından 31 hastanın dahil edildiği çalışmada SPECT-BT nin I-123 MIBG sintigrafisinde planar görüntülemedeki yanlış pozitif değerlendirme-leri önlemedeki katkısı araştırılmıştır. Biyokimyasal (%81) ve/veya klinik (%19) olarak feokromositoma şüphesi olan hastalar değerlendirilmiştir.…”

Section: Discussionunclassified

Comparison of planar imaging with I-123 MIBG scintigraphy and SPECT-CT imaging for pheochromocytoma

Tumar¹,

Özülker²

2018

Okmeydani Medical Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

Comparison of planar imaging with I-123 MIBG scintigraphy and SPECT-CT imaging for pheochromocytoma

Tumar¹,

Özülker²

2018

Okmeydani Medical Journal

View full text Add to dashboard Cite

show abstract

“…PET-CT should be reserved for patients who have negative SSR scintigraphy or additional lesions on CT or MRI that are not SSR avid (21). In the study of neuroendocrine tumors, SPECT-CT scanners contribute to eliminate the uncertainty of physiological accumulation of the radiopharmaceutical (source of false positive) and facilitate correct anatomical location of the findings (22,23).…”

Section: Endocrinologymentioning

confidence: 98%

Multimodality imaging techniques

Martí‐Bonmatí¹,

Sopena²,

Bartumeus³

et al. 2010

Contrast Media & Molecular

127

View full text Add to dashboard Cite

In multimodality imaging, the need to combine morphofunctional information can be approached by either acquiring images at different times (asynchronous), and fused them through digital image manipulation techniques or simultaneously acquiring images (synchronous) and merging them automatically. The asynchronous post-processing solution presents various constraints, mainly conditioned by the different positioning of the patient in the two scans acquired at different times in separated machines. The best solution to achieve consistency in time and space is obtained by the synchronous image acquisition. There are many multimodal technologies in molecular imaging. In this review we will focus on those multimodality image techniques more commonly used in the field of diagnostic imaging (SPECT-CT, PET-CT) and new developments (as PET-MR). The technological innovations and development of new tracers and smart probes are the main key points that will condition multimodality image and diagnostic imaging professionals' future. Although SPECT-CT and PET-CT are standard in most clinical scenarios, MR imaging has some advantages, providing excellent soft-tissue contrast and multidimensional functional, structural and morphological information. The next frontier is to develop efficient detectors and electronics systems capable of detecting two modality signals at the same time. Not only PET-MR but also MR-US or optic-PET will be introduced in clinical scenarios. Even more, MR diffusion-weighted, pharmacokinetic imaging, spectroscopy or functional BOLD imaging will merge with PET tracers to further increase molecular imaging as a relevant medical discipline. Multimodality imaging techniques will play a leading role in relevant clinical applications. The development of new diagnostic imaging research areas, mainly in the field of oncology, cardiology and neuropsychiatry, will impact the way medicine is performed today. Both clinical and experimental multimodality studies, in humans and animals, will have to demonstrate an efficient use of the imaging information provided by the modalities to affect the future of medical imaging.

show abstract

“…(Adapted and reproduced permission of reference [115].) Anatomic localization, evaluation of therapeutic efficacy for pancreatic chemotherapy [180,[191][192][193] Parathyroid gland 99m Tc-sestamibi Anatomical localization [161,[194][195][196][197][198] Pheochromocytoma 123 I-metaiodobenzylguanidine Anatomical localization [189] Prostate cancer 111 In-capromab pendetide Attenuation correction, anatomical localization, monitoring brachytherapy [12,26,[199][200][201][202][203][204] Whole body (phantom study) Technetium-99m Attenuation correction, radioimmunotherapy dosimetry [226] …”

Section: Discussionmentioning

confidence: 99%

Technological Development and Advances in Single-Photon Emission Computed Tomography/Computed Tomography

Seo

Marì

Hasegawa

2008

Seminars in Nuclear Medicine

172

View full text Add to dashboard Cite

SPECT/CT has emerged over the past decade as a means of correlating anatomical information from CT with functional information from SPECT. The integration of SPECT and CT in a single imaging device facilitates anatomical localization of the radiopharmaceutical to differentiate physiological uptake from that associated with disease and patient-specific attenuation correction to improve the visual quality and quantitative accuracy of the SPECT image. The first clinically available SPECT/CT systems performed emission-transmission imaging using a dual-headed SPECT camera and a low-power x-ray CT sub-system. Newer SPECT/CT systems are available with high-power CT sub-systems suitable for detailed anatomical diagnosis, including CT coronary angiography and coronary calcification that can be correlated with myocardial perfusion measurements. The high-performance CT capabilities also offer the potential to improve compensation of partial volume errors for more accurate quantitation of radionuclide measurement of myocardial blood flow and other physiological processes and for radiation dosimetry for radionuclide therapy. In addition, new SPECT technologies are being developed that significantly improve the detection efficiency and spatial resolution for radionuclide imaging of small organs including the heart, brain, and breast, and therefore may provide new capabilities for SPECT/CT imaging in these important clinical applications.

show abstract

Value of combined XCT/SPECT technology for avoiding false positive planar 123I-MIBG scintigraphy

Cited by 33 publications

References 19 publications

Comparison of planar imaging with I-123 MIBG scintigraphy and SPECT-CT imaging for pheochromocytoma

Comparison of planar imaging with I-123 MIBG scintigraphy and SPECT-CT imaging for pheochromocytoma

Multimodality imaging techniques

Technological Development and Advances in Single-Photon Emission Computed Tomography/Computed Tomography

Contact Info

Product

Resources

About